Description
Role Description We are seeking a Computational Biologist/Bioinformatician with a background in immunology and/or oncology to contribute to the Translational Genomics team at Jounce. This person will act as a Translational Genomics lead on early stage programs, performing computational analysis on bulk and single cell gene expression data, interpreting results and helping project teams design new experiments to identify new targets and interrogate immune oncology pathways. This position will take ownership of our high-performance computing and bioinformatics pipelines and workflows, working closely with both bioinformatics analysts and wet lab scientists to increase team capabilities and efficiency. Responsibilities may include upkeep of cancer immunotherapy databases and resources, and administration of bioinformatics cloud-based servers and systems. The ideal candidate will have a record of applying state-of-the-art computational methods to understand biological systems, the ability to understand and explain nuances between algorithms, and the capacity to guide project teams through early stage development.
Responsibilities- Contribute to translational genomics strategy and participate in research team meetings to proactively suggest new ways to impact programs from discovery through the clinic;
- Develop novel algorithms and implement, validate, and maintain shared pipelines for processing of NGS data (targeted/whole exome, RNA, single cell, TCR, and/or BCR sequencing) and downstream analyses (e.g. TMB, HLA typing, MSI status determination, differential transcript expression);
- Keep our portfolio of bioinformatics tools cutting edge by evaluating and recommending pipeline algorithms based on statistical quality and performance metrics on real and simulated data sets;
- Work with other bioinformaticians to build out cloud-based bioinformatics high performance computing capabilities in partnership with our Research Informatics team;
- Manage existing high-dimensional data resources and ingest new public and internal data sets for use by team members; and
- Use best practices for reproducible research and data stewardship.
Qualifications- Ph.D. in Computational Biology, Bioinformatics, Biomedical Engineering, or a related field or a M.S. with 10+ years of relevant experience required;
- Experience with public cancer biology databases and an understanding of how to utilize big data to drive discovery efforts;
- Experience developing novel algorithms, implementing and managing NGS pipelines across a variety of different data types, and aiding in the design of experiments to deepen understanding of biology;
- Deep understanding of next generation sequencing (NGS) methods and how upstream sample preparation and processing may affect sequencing results and their interpretation;
- Strong hands-on programming skills (R/Bioconductor, Python, Matlab, SQL, Bash scripting or similar)
- Proficiency in LINUX system administration, shell scripting, software compilation, and version control systems;
- Familiarity with Amazon Web Services (AWS) or similar cloud-computing services;
- Experience with machine learning, statistical modeling, and/or pathway/network analysis is beneficial;
- Experience with quantitative systems pharmacology is favored;
- Demonstrated problem-solving and data analytical skills;
- Highly organized and motivated individual, able to work well in a group setting as well as independently in a fast-paced environment; and
- Excellent communication skills and the ability to prioritize and deliver research in a fast-paced, milestone-driven environment.
Company Overview Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit .
Diversity and Inclusion Statement Jounce strives to create a workplace that reflects the diversity of cancer patients, and where all feel included and valued
because of their differences. Actively including people who add to our culture and enhance our values leads to better decisions and outcomes for those we serve - patients,
all patients. Beyond our walls, our focus is on addressing inequities in opportunities for STEM education, careers opportunities in Biotech, and access to cancer care.
Equal Opportunity Employer Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.
